Product Description
the oral prodrug for the company's Group IIÊmGluR2/3 antagonist, BCI-632. BCI-838 may yield meaningful clinical benefits for patients suffering from TRD. We believe that BCI-838 may generate early antidepressant responses similar to ketamine with a better safety profile and less adverse event liability. Unlike ketamine, BCI-838 is an oral drug with no need for intravenous administration (Sourced from: https://www.prnewswire.com/news-releases/braincells-inc-announces-the-successful-completion-of-a-multiple-ascending-dose-study-of-bci-838-a-group-ii-mglur23-antagonist-and-the-companys-plans-for-a-proof-of-concept-study-in-patients-with-treatment-resistant-depress-182166091.html)
Mechanisms of Action: mGLUr Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BrainCells
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Depressive Disorder, Treatment-Resistant|Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BCI-632-CL-003 | P1 |
Completed |
Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant |
2012-04-01 |
|
| BCI-632-CL-002 | P1 |
Completed |
Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant |
2012-01-01 |